CardiaTec Bio
CardiaTec Biosciences uses large-scale human cardiac multiomics and clinical data to identify new targets and therapies for cardiovascular disease. The company combines AI and computational modeling with a proprietary human heart multiomics dataset—sourced from a global network of clinical partners—to map disease biology and prioritize first-in-class therapeutic candidates. CardiaTec operates as a TechBio drug-discovery platform, integrating machine learning, multiomic analysis, and clinical annotation to accelerate translational pathways. Its team brings industry drug discovery experience and the dataset underpins partnerships with biopharma for target validation and preclinical development. The approach targets the cardiovascular therapeutics market by enabling human-data-driven discovery and clearer routes to clinical translation.
CardiaTec Bio
CardiaTec Biosciences uses large-scale human cardiac multiomics and clinical data to identify new targets and therapies for cardiovascular disease. The company combines AI and computational modeling with a proprietary human heart multiomics dataset—sourced from a global network of clinical partners—to map disease biology and prioritize first-in-class therapeutic candidates. CardiaTec operates as a TechBio drug-discovery platform, integrating machine learning, multiomic analysis, and clinical annotation to accelerate translational pathways. Its team brings industry drug discovery experience and the dataset underpins partnerships with biopharma for target validation and preclinical development. The approach targets the cardiovascular therapeutics market by enabling human-data-driven discovery and clearer routes to clinical translation.
